Evidence map›Paper›PMID 34476245›Full record

ArticleERJ open research2021

Quantitative

Laurence Vass, Marie Fisk, Joseph Cheriyan, Divya Mohan, Julia Forman, Adelola Oseni, Anand Devaraj, Kaisa M Mäki-Petäjä, Carmel M McEniery, Jonathan Fuld and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. HighERJ open research · 2026
    Article
  4. Article
  5. Article
  6. AnJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Laurence VassDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK.
Marie FiskDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK.
Joseph CheriyanDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK.
Divya MohanGSK RD, Collegeville, PA, USA.ORCID https://orcid.org/0000-0001-9153-2683
Julia FormanCambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Adelola OseniDept of Radiology, St George's Hospital NHS Trust, London, UK.
Anand DevarajNational Heart and Lung Institute, Imperial College, London, UK.
Kaisa M Mäki-PetäjäDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK.
Carmel M McEnieryDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK.
Jonathan FuldDivision of Respiratory Medicine, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Nicholas S HopkinsonNational Heart and Lung Institute, Imperial College, London, UK.ORCID https://orcid.org/0000-0003-3235-0454
David A LomasUCL Respiratory, Division of Medicine, University College London, London, UK.
John R CockcroftDept of Cardiology, Wales Heart Research Institute, Cardiff University, Cardiff, UK.
Ruth Tal-SingerGSK RD, Collegeville, PA, USA.ORCID https://orcid.org/0000-0002-5275-8062
Michael I PolkeyNational Heart and Lung Institute, Imperial College, London, UK.
Ian B WilkinsonDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK.
University of Cambridge · GBImperial College London · GBCambridge University Hospitals NHS Foundation Trust · GBCardiff University · GBSt George's Hospital · GBUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleCOPD and smoking are characterised by pulmonary inflammation.

objectivesTo evaluate pulmonary inflammation, assessed by FDG uptake, in whole and regional lung in "usual" (smoking-related) COPD patients, alpha-1 antitrypsin deficiency (α

methodsData from two imaging studies were evaluated. Pulmonary FDG uptake (normalised K

resultsCOPD patients, α

conclusionsFDG PET/CT has potential as a noninvasive tool to enable whole lung and regional quantification of FDG uptake to assess smoking- and COPD-related pulmonary inflammation.

Identifiers

PMID34476245
PMCPMC8405867
OpenAlexW3163657765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.